The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PERISYL COMBI (Alphapharm Pty Ltd)
Product name
PERISYL COMBI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
106 (255 working days)
Active ingredients
indapamide hemihydrate; perindopril erbumine
Registration type
New generic medicine
Indication
PERISYL COMBI 4/1.25 (tablet) is indicated for:
- Treatment of hypertension. Treatment should not be initiated with this combination.
PERISYL COMBI 2/0.625 (tablet) is indicated for:
- Treatment of hypertension.